

# United States Department of Agriculture Animal and Plant Health Inspection Service

WCAMPBELL **2016090000778535** Insp. id

#### **Inspection Report**

Phoenix Pharmaceuticals Inc. Customer ID: 1288

330 Beach Road Certificate: 93-R-0382 Burlingame, CA 94010

Site: 002

PHOENIX PHARMACEUTICALS,

INC.

Type: ROUTINE INSPECTION

Date: 24-MAR-2022

2.31(c)(3) Repeat

Institutional Animal Care and Use Committee (IACUC).

After the facility's last program review and facility inspection in October 2021, the Institutional Animal Care and Use Committee (IACUC) failed to prepare and submit a report to the Institutional Official (IO) as required.

Failure of the IACUC to submit reports to the IO could prevent the IO from making corrective actions in program deficiencies that are or could impact animal welfare.

The IACUC shall prepare reports of its evaluations and submit the reports to the IO. The reports must contain a description of any deficiencies and contain a reasonable and specific plan and schedule with dates for correcting each deficiency.

Correct from this point forward.

2.31(d)(1)(iii)

Institutional Animal Care and Use Committee (IACUC).

Upon review of the facility's animal use protocol for the immunization of Rabbits for antibody production, a written assurance that the activities do not unnecessarily duplicate previous experiments was not provided.

Failure to ensure that the proposed activities meet each of the requirements of the regulation could result in a negative impact of the animals' welfare.

Prepared By: WILLIAM CAMPBELL Date:

Title: VETERINARY MEDICAL

**OFFICER** 

Received by Title: Facility Representative Date:

28-MAR-2022

28-MAR-2022

USDA, APHIS, Animal Care



# United States Department of Agriculture Animal and Plant Health Inspection Service

WCAMPBELL **2016090000778535** Insp\_id

### **Inspection Report**

Written assurance of the above requirement must be provided.

Correct by April 30, 2022

#### 2.31(e)

#### Institutional Animal Care and Use Committee (IACUC).

Upon review of the facility's animal use protocol for the immunization of Rabbits for antibody production, there is no description of the approximate number of animals to be used. A rational for involving animals, and for the appropriateness of the species and numbers of animals to be used is not provided. There isn't a complete description of the proposed use of the animals, and there isn't a description of procedures designed to assure that discomfort and pain to animals will be limited to that which, is unavoidable for the conduct of scientifically valuable research.

Each protocol for animal use must contain all aspects of the cited regulation to allow the IACUC to fully understand and adequately review the proposed activities.

Correct by April 30, 2022.

This inspection and exit interview were conducted with a facility representative.

Prepared By: WILLIAM CAMPBELL Date:

Title: VETERINARY MEDICAL

**OFFICER** 

Received by Title: Facility Representative Date:

28-MAR-2022

28-MAR-2022

USDA, APHIS, Animal Care



### United States Department of Agriculture Animal and Plant Health Inspection Service

Customer: 1288

Inspection Date: 24-Mar-2022

## **Species Inspected**

Cust No	Cert No	Site	Site Name	Inspection
1288	93-R-0382	002	PHOENIX PHARMACEUTICALS, INC.	24-MAR-2022

Count **Scientific Name Common Name** 

DOMESTIC RABBIT / EUROPEAN 000016 Oryctolagus cuniculus

**RABBIT** 

000016 Total